The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IOVA | +8.67% | -86.84% | -33.34% | -28% |
| S&P | +18.89% | +78.8% | +12.32% | +588% |
Iovance Biotherapeutics, Inc. is a biopharmaceutical company, which engages in the development and commercialization of cell therapies as novel cancer immunotherapy products. Its lead product candidate, LN-144 for metastatic melanoma, is an autologous adoptive cell therapy utilizing tumor-infiltrating lymphocytes (TIL), which are T cells derived from patients' tumors. The company was founded by Robert T. Brooke on September 17, 2007, and is headquartered in San Carlos, CA.
The company is studying its approved drug for many other indications.
Iovance has a long way to go to get to a break-even point, but the company has been showing progress.
| Q4 2025 | YOY Change | |
|---|---|---|
| Revenue | $86.71M | 17.7% |
| Gross Profit | $34.08M | 54.8% |
| Gross Margin | 39.31% | 9.4% |
| Market Cap | $1.08B | -51.9% |
| Market Cap / Employee | $1.11M | 0.0% |
| Employees | 975 | 16.3% |
| Net Income | -$71,904.00K | 8.5% |
| EBITDA | -$60,876.00K | 18.7% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q4 2025 | YOY Change | |
|---|---|---|
| Net Cash | $163.08M | 41.0% |
| Accounts Receivable | $82.45M | 18.9% |
| Inventory | 51.7 | 0.3% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $44.40M | -2.1% |
| Short Term Debt | $5.04M | -60.9% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -42.88% | 1.1% |
| Return On Invested Capital | -54.63% | 3.2% |
| Q4 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$61,885.00K | 20.1% |
| Operating Free Cash Flow | -$52,565.00K | 28.3% |
| Metric | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 1.43 | 0.75 | 1.06 | 1.50 | -48.59% |
| Price to Sales | 5.06 | 2.38 | 3.15 | 4.22 | -69.33% |
| Price to Tangible Book Value | 2.38 | 1.19 | 1.84 | 2.52 | -47.75% |
| Enterprise Value to EBITDA | -6.98 | -3.21 | -6.94 | -14.18 | -46.64% |
| Return on Equity | -51.8% | -53.2% | -53.9% | -55.5% | -3.45% |
| Total Debt | $53.72M | $53.17M | $52.49M | $49.44M | -15.13% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
